Domainex announces the grant of US and European patents for its lead programme, targeting IKK epsilon and TBK1 for the Treatment of diseases such as COPD and Psoriasis

Domainex’s R&D portfolio has a focus on targets for inflammation and cancer treatments and the Company is in discussion with potential partners to work with Domainex to take these programmes forward.

Notes for Editor

About Domainex

• Founded in 2002, Domainex is based in Cambridge, UK.
• Domainex is a privately-owned revenue-generating company. It has attracted investment from UCLB, the Bloomsbury Bioseed Fund, Longbow Capital, The Capital Fund (managed by YFM Venture Finance), Bury-Fitzwilliam, Juno Capital, and from Takeda Research Investments. The UK’s Biomedical Catalyst, run jointly by the Technology Strategy Board and the Medical Research Council, has also supported Domainex’s work on COPD drug discovery.
• Major discovery ‘gaps’ exist between the vast amount of genomic information that is now available, the accessibility of the corresponding proteins for use in target validation and drug discovery, and the identification of robust hits in a cost-effective manner. Domainex utilises its proprietary platform technologies in order to solve these challenges, which enables it to tackleexciting but challenging drug targets in order to deliver novel and potentially life-saving therapies for COPD and cancer.
• Domainex’s discovery platform enables rapid progression of drug discovery projects from novel target through to candidate drug by means of its Combinatorial DomainHunting (CDH) technology, LeadBuilder virtual hit screening software, and its integrated approach to medicinal and computational chemistry.

Media Relations:             Sylvie Berrebi